Link between Genotype and Multi-Organ Iron and Complications in Children with Transfusion-Dependent Thalassemia
- PMID: 35330400
- PMCID: PMC8950605
- DOI: 10.3390/jpm12030400
Link between Genotype and Multi-Organ Iron and Complications in Children with Transfusion-Dependent Thalassemia
Abstract
We evaluated the impact of the genotype on hepatic, pancreatic and myocardial iron content, and on hepatic, cardiac and endocrine complications in children with transfusion-dependent β-thalassemia (β-TDT). We considered 68 β-TDT patients (11.98 ± 3.67 years, 51.5% females) consecutively enrolled in the Extension-Myocardial Iron Overload in Thalassemia network. Iron overload was quantified by T2* technique and biventricular function by cine images. Replacement myocardial fibrosis was evaluated by late gadolinium enhancement technique. Three groups of patients were identified: homozygous β+ (N = 19), compound heterozygous β0β+ (N = 24), and homozygous β0 (N = 25). The homozygous β0 group showed significantly lower global heart and pancreas T2* values than the homozygous β+ group. Compared to patients with homozygous β+ genotype, β0β+ as well as β0β0 patients were more likely to have pancreatic iron overload (odds ratio = 6.53 and 10.08, respectively). No difference was detected in biventricular function parameters and frequency of replacement fibrosis. No patient had cirrhosis/fibrosis, diabetes or heart failure, and the frequency of endocrinopathies was comparable among the groups. In pediatric β-TDT patients, there is an association between genotype and cardiac and pancreatic iron overload. The knowledge of patients' genotype can be valuable in predicting some patients' phenotypic features and in helping the clinical management of β-TDT patients.
Keywords: complications; genotype; iron overload; transfusion-dependent thalassemia.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia.Ann Hematol. 2024 Jun;103(6):1887-1896. doi: 10.1007/s00277-024-05741-9. Epub 2024 Apr 6. Ann Hematol. 2024. PMID: 38581547
-
Pancreatic fatty replacement as risk marker for altered glucose metabolism and cardiac iron and complications in thalassemia major.Eur Radiol. 2023 Oct;33(10):7215-7225. doi: 10.1007/s00330-023-09630-z. Epub 2023 Apr 28. Eur Radiol. 2023. PMID: 37115218 Free PMC article.
-
Multiparametric cardiac magnetic resonance in patients with thalassemia intermedia: new insights from the E-MIOT network.Radiol Med. 2024 Jun;129(6):879-889. doi: 10.1007/s11547-024-01821-y. Epub 2024 Apr 29. Radiol Med. 2024. PMID: 38683500
-
Thalassemia.Hematology Am Soc Hematol Educ Program. 2004:14-34. doi: 10.1182/asheducation-2004.1.14. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561674 Review.
-
Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.Clin Ther. 2020 Feb;42(2):322-337.e2. doi: 10.1016/j.clinthera.2019.12.003. Epub 2019 Dec 24. Clin Ther. 2020. PMID: 31882227
Cited by
-
Special Issue "Personalized Medicine in Blood Disease of Children".J Pers Med. 2024 Mar 5;14(3):285. doi: 10.3390/jpm14030285. J Pers Med. 2024. PMID: 38541027 Free PMC article.
-
Recent advancements in glucose dysregulation and pharmacological management of osteoporosis in transfusion-dependent thalassemia (TDT): an update of ICET-A (International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine).Acta Biomed. 2023 Jun 14;94(3):e2023178. doi: 10.23750/abm.v94i3.14805. Acta Biomed. 2023. PMID: 37326257 Free PMC article. Review.
-
New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.Diagnostics (Basel). 2022 Aug 9;12(8):1921. doi: 10.3390/diagnostics12081921. Diagnostics (Basel). 2022. PMID: 36010271 Free PMC article. Review.
-
Genetic Correlation of HBB, HFE and HAMP Genes to Endocrinal Complications in Egyptian Beta Thalassemia Major Patients.Biochem Genet. 2025 Aug;63(4):3267-3286. doi: 10.1007/s10528-024-10868-5. Epub 2024 Jul 2. Biochem Genet. 2025. PMID: 38954212
References
-
- Thein S.L. Genetic modifiers of beta-thalassemia. Haematologica. 2005;90:649–660. - PubMed
-
- Cappellini M.D., Cohen A., Porter J., Taher A., Viprakasit V. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) 3rd ed. Thalassaemia International Federation; Nicosia, Cyprus: 2014. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources